白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

聂力; 葛卫红

doi:10.3969/j.issn.1006-0111.2017.06.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

聂力, 葛卫红

文章导航 > 药学实践与服务 > 2017 > 35(6): 562-564,568

聂力, 葛卫红. 白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析[J]. 药学实践与服务, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

引用本文:

聂力, 葛卫红. 白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析[J]. 药学实践与服务, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

NIE Li, GE Weihong. Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

Citation:

NIE Li, GE Weihong. Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

doi: 10.3969/j.issn.1006-0111.2017.06.020

聂力,
葛卫红

南京大学医学院附属鼓楼医院药学部, 江苏南京 210008

Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients

NIE Li,
GE Weihong

Department of Pharmacy, Nanjing Drum Tower Hospital Affiliated to Medical College, Nanjing University, Nanjing 210008, China

摘要: 目的分析白三烯受体拮抗剂在哮喘患者中的抗炎、改善免疫功能的效果。方法选取鼓楼医院2014年8月至12月收治的86例哮喘患者为研究对象，随机分为对照组（43例）和观察组（43例），对照组采用常规治疗+沙美特罗替卡松粉吸入剂（舒利迭50 μg/250 μg），观察组在对照组的基础上采用白三烯受体拮抗剂（孟鲁司特钠片），两组疗程均为14 d。比较两组炎性因子、免疫功能的变化，以评估治疗方案的有效性，同时比较两组的不良反应。结果观察组的炎性因子如IL-6、TNF-α及CRP较之对照组均有所降低，差异有统计学意义（P<0.05）。观察组的免疫功能指标如CD4⁺、CD4⁺/CD8⁺高于对照组，CD8⁺均低于对照组，差异有统计学意义（P<0.05）。观察组经治疗后的ACT评分较之对照组有所提高，且总有效率也高于对照组，差异有统计学意义（P<0.05）。两组患者在治疗过程中均未出现明显不良反应。结论白三烯拮抗剂（孟鲁司特）在哮喘治疗中能够发挥抗炎和改善免疫功能的效果，这可能是其提高哮喘治疗效果的重要机制。
- 白三烯受体拮抗剂 /
- 哮喘 /
- 抗炎 /
- 免疫功能
Abstract: Objective To analyze the effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients. Methods 86 cases of asthma patients in our hospital from August to December 2014 were taken as the research objects, they were randomly divided into the observation group with 43 cases and the control group with 43 cases, the control group was treated with conventional therapy plus Seretide, the observation group was given leukotriene receptor antagonist-montelukast based on the control group, two groups were treated for 14 d. The changes of inflammatory factors and immune function, therapeutic effect, adverse reaction were compared between the two groups after treatment. In the observation group after the treatment,the IL-6, TNF-α and CRP were lower than that in the control group, the difference was statistically significant (P<0.05). In the observation group after the treatment, CD4⁺ and CD4⁺/CD8⁺ were higher than that in the control group, CD8⁺ was lower than that in the control group, the difference was statistically significant (P<0.05). After the treatment in the observation group, the ACT score was higher than that in the control group, the total effective rate was higher than that in the control group, the difference was statistically significant (P<0.05). There was no obvious adverse reaction in the two groups. Conclusion Leukotriene antagonist (montelukast) could play an important role in improving the immune function and anti-inflammation in asthma patients, which might be an important mechanism to improve the therapeutic effect of asthma.
- leukotriene receptor antagonist /
- asthma /
- anti-inflammatory /
- immune function

[1]	Ali Assad N,Sood A.Leptin,adiponectin and pulmonary diseases[J].Biochimie,2012,94(10):2180-2189.
[2]	Rubini A.Interleukin-6 and lung inflammation:evidence for a causative role in inducing respiratory system resistance increments[J].Inflamm Allergy Drug Targets,2013,12(5):315-321.
[3]	马红梅,刘香莲.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的作用分析[J].海南医学院学报,2015,21(3):350-352.
[4]	林江涛,祝墡珠,王家骥,等.中国支气管哮喘防治指南(基层版)[J].中国实用内科杂志,2013,33(8):615-622.
[5]	李爱华.舒利迭联合孟鲁司特钠治疗支气管哮喘的临床研究[J].中国现代医生,2013,51(16):67-68.
[6]	邓俊,杨艳,梁宇佳,等.孟鲁司特对哮喘大鼠气道炎症的调控作用及其机制[J].山东医药,2016,56(24):34-36.
[7]	姜增凯,贾萍,叶晓歌. 孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效及其对炎性因子、肺功能、免疫功能的影响研究[J].实用心脑肺血管病杂志,2016,24(4):49-52.
[8]	夏玉平,方圆.孟鲁司特钠联合阿奇霉素对支原体肺炎儿童免疫功能及肺功能的影响[J].海南医学院学报,2016,22(18):2115-2117.
[9]	黄艳春,肖强.孟鲁司特钠对哮喘患儿免疫指标及促炎因子的影响[J].现代中西医结合杂志,2014,23(29):3252-3254.
[10]	吴红样.孟鲁司特联合舒利迭对哮喘急性发作期患者疗效及免疫功能的影响[J].中国微生态学杂志,2015,27(5):568-570.
[11]	孔黎明,孔金阁.舒利迭联合孟鲁司特对咳嗽变异性哮喘患儿的疗效及其对IL13、Ig E的影响[J].医学临床研究,2013,30(12):2353-2355.

[1]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[2]	徐飞, 刘盈, 殷佳, 诸国樑, 练鲁英. 上海某三级公立医院药品管理内部控制评价实践研究 . 药学实践与服务, 2024, 42(12): 542-548. doi: 10.12206/j.issn.2097-2024.202402003
[3]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[4]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[5]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
[6]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[7]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[8]	宋泽成, 马闪闪, 胡巧灵, 仲华, 王彦. 小檗碱与氟康唑合用抗白念珠菌耐受菌的研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202409047
[9]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[10]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[11]	邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴. 虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
[12]	关梦瑶, 夏天爽, 何旭辉, 蒋益萍, 辛海量. 黑蒜多糖抗便秘作用研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202403059
[13]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 . 药学实践与服务, 2024, 42(12): 524-527, 532. doi: 10.12206/j.issn.2097-2024.202405035
[14]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[15]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050

点击查看大图

计量

文章访问数: 3477
HTML全文浏览量: 351
PDF下载量: 495
被引次数: 0

白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

doi: 10.3969/j.issn.1006-0111.2017.06.020

聂力,
葛卫红

南京大学医学院附属鼓楼医院药学部, 江苏南京 210008

收稿日期: 2017-06-15
修回日期: 2017-10-23

关键词:

白三烯受体拮抗剂 /

哮喘 /

抗炎 /

免疫功能

摘要: 目的分析白三烯受体拮抗剂在哮喘患者中的抗炎、改善免疫功能的效果。方法选取鼓楼医院2014年8月至12月收治的86例哮喘患者为研究对象，随机分为对照组（43例）和观察组（43例），对照组采用常规治疗+沙美特罗替卡松粉吸入剂（舒利迭50 μg/250 μg），观察组在对照组的基础上采用白三烯受体拮抗剂（孟鲁司特钠片），两组疗程均为14 d。比较两组炎性因子、免疫功能的变化，以评估治疗方案的有效性，同时比较两组的不良反应。结果观察组的炎性因子如IL-6、TNF-α及CRP较之对照组均有所降低，差异有统计学意义（P<0.05）。观察组的免疫功能指标如CD4⁺、CD4⁺/CD8⁺高于对照组，CD8⁺均低于对照组，差异有统计学意义（P<0.05）。观察组经治疗后的ACT评分较之对照组有所提高，且总有效率也高于对照组，差异有统计学意义（P<0.05）。两组患者在治疗过程中均未出现明显不良反应。结论白三烯拮抗剂（孟鲁司特）在哮喘治疗中能够发挥抗炎和改善免疫功能的效果，这可能是其提高哮喘治疗效果的重要机制。

English Abstract

Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients

NIE Li,
GE Weihong

Department of Pharmacy, Nanjing Drum Tower Hospital Affiliated to Medical College, Nanjing University, Nanjing 210008, China

Received Date: 2017-06-15
Rev Recd Date: 2017-10-23

Keywords:

Abstract: Objective To analyze the effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients. Methods 86 cases of asthma patients in our hospital from August to December 2014 were taken as the research objects, they were randomly divided into the observation group with 43 cases and the control group with 43 cases, the control group was treated with conventional therapy plus Seretide, the observation group was given leukotriene receptor antagonist-montelukast based on the control group, two groups were treated for 14 d. The changes of inflammatory factors and immune function, therapeutic effect, adverse reaction were compared between the two groups after treatment. In the observation group after the treatment,the IL-6, TNF-α and CRP were lower than that in the control group, the difference was statistically significant (P<0.05). In the observation group after the treatment, CD4⁺ and CD4⁺/CD8⁺ were higher than that in the control group, CD8⁺ was lower than that in the control group, the difference was statistically significant (P<0.05). After the treatment in the observation group, the ACT score was higher than that in the control group, the total effective rate was higher than that in the control group, the difference was statistically significant (P<0.05). There was no obvious adverse reaction in the two groups. Conclusion Leukotriene antagonist (montelukast) could play an important role in improving the immune function and anti-inflammation in asthma patients, which might be an important mechanism to improve the therapeutic effect of asthma.

聂力, 葛卫红. 白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析[J]. 药学实践与服务, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

引用本文:

聂力, 葛卫红. 白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析[J]. 药学实践与服务, 2017, 35(6): 562-564,568. doi: 10.3969/j.issn.1006-0111.2017.06.020

Citation:

全文HTML

参考文献 (11)

下载: 全尺寸图片幻灯片

返回文章

用微信扫码二维码

分享至好友和朋友圈

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发

留言板

白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

doi: 10.3969/j.issn.1006-0111.2017.06.020

Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients

计量

出版历程

白三烯受体拮抗剂改善哮喘患者炎症及免疫功能的效果分析

doi: 10.3969/j.issn.1006-0111.2017.06.020

南京大学医学院附属鼓楼医院药学部, 江苏 南京 210008

English Abstract

Effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients

Department of Pharmacy, Nanjing Drum Tower Hospital Affiliated to Medical College, Nanjing University, Nanjing 210008, China

全文HTML

目录

南京大学医学院附属鼓楼医院药学部, 江苏南京 210008